BOSTON SCIENTIFIC CORP shareholders Q3 2023

BOSTON SCIENTIFIC CORP's ticker is BSX and the CUSIP is 101137107. A total of 1,027 filers reported holding BOSTON SCIENTIFIC CORP in Q3 2023. The put-call ratio across all filers is 1.27 and the average weighting 0.3%.

BOSTON SCIENTIFIC CORP shareholders Q3 2023
Name	Shares	Value	Weighting ↓
Point72 Europe (London) LLP	305,793	$16,145,870	0.99%
Point72 Asset Management, L.P.	6,421,754	$339,068,611	0.99%
Dana Investment Advisors, Inc.	366,296	$19,340,429	0.99%
LOCKHEED MARTIN INVESTMENT MANAGEMENT CO	271,332	$12,771,963	0.98%
Ulland Investment Advisors, LLC	16,224	$857	0.94%
Van Leeuwen & Company, LLC	28,384	$1,499	0.93%
Ardevora Asset Management LLP	355,856	$18,789	0.92%
Financiere des Professionnels - Fonds d,investissement inc.	181,953	$9,607,119	0.92%
abrdn plc	6,714,894	$354,546,404	0.90%
Mount Lucas Management LP	48,074	$2,538,307	0.90%
ASSOCIATED BANC-CORP	430,188	$22,713,926	0.88%
Rathbones Group PLC	2,262,822	$119,477,001	0.87%
Accurate Wealth Management, LLC	54,513	$2,750,726	0.86%
Tredje AP-fonden	1,106,017	$58,397,697	0.86%
COOKSON PEIRCE & CO INC	241,912	$12,773	0.84%
Marks Group Wealth Management, Inc	127,048	$6,708,134	0.83%
Schear Investment Advisers, LLC	14,304	$755,251	0.82%
Ninety One UK Ltd	4,860,826	$256,651,613	0.81%
FRED ALGER MANAGEMENT, LLC	2,596,472	$137,093,722	0.79%
Knights of Columbus Asset Advisors LLC	161,933	$8,550,062	0.78%

About BOSTON SCIENTIFIC CORP

Boston Scientific Corp is a leading medical device company that specializes in developing innovative medical technologies. The company has a strong presence in the global market and is known for its high-quality products and services. Boston Scientific Corp has a diverse portfolio of products that cater to a wide range of medical needs, including cardiovascular, urology, and endoscopy.

The company has a strong leadership team, with Michael F. Mahoney serving as the CEO and Chairman of the Board. Under his leadership, Boston Scientific Corp has continued to grow and expand its operations. The company has a strong focus on research and development, with a significant portion of its revenue being invested in this area.

Boston Scientific Corp has also been actively involved in mergers and acquisitions, which has helped the company to expand its product portfolio and enter new markets. In 2018, the company acquired NxThera, a medical device company that specializes in treating prostate conditions. This acquisition has helped Boston Scientific Corp to strengthen its position in the urology market.

Overall, Boston Scientific Corp is a strong and reliable company that is well-positioned for future growth. With a strong leadership team, a diverse portfolio of products, and a focus on research and development, the company is poised to continue its success in the global medical device market.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BOSTON SCIENTIFIC CORP's shareholders in Q3 2023. To view BOSTON SCIENTIFIC CORP's shareholder history, click here.